AstraZeneca plc (AZN) Receives Average Recommendation of “Hold” from Analysts

Shares of AstraZeneca plc (NYSE:AZN) have received an average recommendation of “Hold” from the twenty-six analysts that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $34.73.

A number of brokerages recently commented on AZN. BMO Capital Markets reaffirmed a “buy” rating and issued a $38.00 target price on shares of AstraZeneca in a research report on Tuesday, November 7th. Sanford C. Bernstein boosted their target price on AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Leerink Swann boosted their target price on AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a research report on Tuesday, February 6th. Citigroup raised AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Finally, Cowen reaffirmed a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a research report on Tuesday, October 17th.

Shares of AstraZeneca (AZN) traded down $0.03 during trading on Tuesday, reaching $34.06. The company had a trading volume of 2,670,945 shares, compared to its average volume of 4,538,228. AstraZeneca has a twelve month low of $28.43 and a twelve month high of $36.70. The company has a market cap of $85,110.00, a price-to-earnings ratio of 28.86, a price-to-earnings-growth ratio of 2.03 and a beta of 0.74. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62.

AstraZeneca (NYSE:AZN) last issued its earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.86. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The business had revenue of $5.78 billion during the quarter, compared to analyst estimates of $5.49 billion. During the same period in the previous year, the company posted $1.21 EPS. The firm’s revenue was up 3.4% compared to the same quarter last year. sell-side analysts predict that AstraZeneca will post 1.67 earnings per share for the current fiscal year.

The business also recently disclosed a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be issued a dividend of $0.95 per share. This represents a yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s dividend payout ratio is currently 116.10%.

Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN increased its holdings in AstraZeneca by 7.6% during the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after purchasing an additional 310,389 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in AstraZeneca by 103.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares in the last quarter. Zions Bancorporation increased its holdings in AstraZeneca by 2,719.4% during the 3rd quarter. Zions Bancorporation now owns 38,852 shares of the company’s stock worth $1,317,000 after purchasing an additional 37,474 shares in the last quarter. Wrapmanager Inc. increased its holdings in AstraZeneca by 21.1% during the 3rd quarter. Wrapmanager Inc. now owns 52,340 shares of the company’s stock worth $1,773,000 after purchasing an additional 9,120 shares in the last quarter. Finally, BB&T Investment Services Inc. increased its holdings in AstraZeneca by 54.9% during the 3rd quarter. BB&T Investment Services Inc. now owns 23,136 shares of the company’s stock worth $782,000 after purchasing an additional 8,199 shares in the last quarter. 14.75% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/13/astrazeneca-plc-azn-receives-average-recommendation-of-hold-from-analysts.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply